Scandipharm (US) targets bronchitis market
This article was originally published in Clinica
Scandipharm (US) has received US FDA clearance to market its Flutter mucus removal device for patients with chronic bronchitis and bronchiectasis. The hand-held device, which was cleared for use by cystic fibrosis sufferers last August (see Clinica No 617, p 19), effectively shakes mucus from the air passages through vibrations caused by a moving steel ball.
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.